Recent analyses in the US Tissue Banking Market underscore a rapid rise in demand for high‐quality, ethically sourced tissues and organs, driven by advances in regenerative medicine, organ transplantation, and novel engineered tissue implants. With improvements in cryopreservation—such as vitrification, ice‐free preservation, and novel cryoprotectants—tissue banks are rethinking storage duration, viability, and transplant success rates. The challenges are multifold: optimizing cooling/warming rates to avoid ice crystal damage, ensuring sterility during long‐term storage, reducing costs of expensive reagents and infrastructure, and meeting regulatory and ethical oversight. As patient expectations rise and surgical techniques become more precise, the viability of banked tissue becomes a critical parameter for success. Investment in research and infrastructure is accelerating, but so too is regulatory scrutiny; tissue banks must adhere to FDA guidelines, donor consent policies, and traceability standards. The interplay between technology, regulation, and ethical sourcing is defining how tissue banking scales in both capacity and quality.

Exploring the technical innovations in cryopreservation invites discussion of what truly constitutes “viability” post‐storage, and how much trade‐off between cost and outcomes acceptable to stakeholders. Consider the financial burden of upgrading cryogenic storage systems, training personnel, and ensuring compliance versus the potential lifesaving and therapeutic benefits. Ethical concerns over donor consent, equity in access to tissue banked materials, and long‐term safety also warrant careful deliberation. Lastly, debate whether current regulatory frameworks are keeping up with such innovations or if policy reforms are needed to ensure both innovation and safety.